LeserbriefKommentar
Sintilimab and Cardiovascular Toxicity—Reply
JAMA · 2024
DOI: 10.1001/jama.2024.0676 ↗Kurz gefasst
Leserbrief in der Zeitschrift JAMA, 2024. Verfasst von Jianming Xu und 1 weiteren Autor:innen. Beteiligte Einrichtung: The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Cardiovascular Diseases, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Antibodies, Monoclonal, HumanizedCardiovascular DiseasesImmune Checkpoint InhibitorsAntineoplastic Combined Chemotherapy ProtocolsCardiovascular SystemHeartRandomized Controlled Trials as TopicMyocarditisCreatine Kinase, MB FormBiomarkers
Substanzen
Antibodies, Monoclonal, HumanizedsintilimabCreatine Kinase, MB FormBiomarkersImmune Checkpoint Inhibitors
Autor:innen und Institutionen
- The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.
Zitieren
APA
Xu, J., & ORIENT-16 Investigators (2024). Sintilimab and Cardiovascular Toxicity—Reply. JAMA. https://doi.org/10.1001/jama.2024.0676
Vancouver
Xu J, ORIENT-16 Investigators. Sintilimab and Cardiovascular Toxicity—Reply. JAMA. 2024. doi:10.1001/jama.2024.0676
BibTeX
@article{Xu2024,
author = {Xu, Jianming and ORIENT-16 Investigators, ORIENT-16 Investigators},
title = {Sintilimab and Cardiovascular Toxicity—Reply},
journal = {JAMA},
year = {2024},
doi = {10.1001/jama.2024.0676}
}
EUVIMED